

1 **Newborn dried blood spots for serological surveys of COVID-19**

2

3 Feimei Liu, BS^{*1,2}, Mytien Nguyen^{1,3}, MS*, Pavithra Vijayakumar³, BS*, Alanna Kaplan³, PhD,

4 Amit Meir⁴, PhD, Yile Dai¹, BS, Eric Wang¹, BS, Hannah Walsh⁶, BS, Aaron M. Ring¹, MD PhD,

5 Saad B. Omer^{5,6,7}, MBBS PhD, and Shelli F. Farhadian, MD PhD⁶

6

7 *These authors contributed equally

8

9 ¹ Department of Immunobiology, Yale School of Medicine, New Haven, CT

10 ²Yale School of Engineering and Applied Science, New Haven, CT

11 ³Yale School of Medicine, New Haven, CT

12 ⁴Boyer Center for Molecular Medicine, Department of Microbial Pathogenesis, Yale University

13 ⁵Yale Institute for Global Health

14

15 ⁶Department of Internal Medicine (Infectious Diseases), Yale School of Medicine, New Haven,
16 Connecticut.

17

18 ⁷Department of Epidemiology of Microbial Diseases, Yale School of Public Health, New Haven,
19 Connecticut.

20

21 **Corresponding author:**

22 Shelli F. Farhadian MD PhD

23 135 College St, New Haven, CT 06510

24 shelli.farhadian@yale.edu

25

26

27 **Abstract**

28 There is an urgent need for inexpensive, population-wide surveillance testing for COVID-19. We
29 tested newborn dried blood spots (DBS) anti-SARS-COV-2 antibodies for all infants born at Yale
30 from March-May 2020, and found that newborn DBS serologies reflect maternal and
31 population-wide infection rates during the study period. This suggests a role for DBS in COVID-
32 19 surveillance in areas where viral testing is limited.

33

34

35 **Introduction**

36 Population seroprevalence surveys are important tools for COVID-19 public health decision-
37 making. However, there are significant hurdles to implementing large-scale serological surveys,
38 especially in resource poor settings. Newborn dried blood spot (DBS) is an easy, inexpensive,
39 and widely used method to collect and store newborn blood specimens, and, in cases where
40 newborn antibody results reflect maternal seropositivity, DBS is an appealing tool to measure
41 COVID-19 population seroprevalence trends among pregnant women.¹ Here, we evaluated DBS
42 as a potential COVID-19 surveillance tool.

43

44 **Methods**

45 Discarded newborn DBS was obtained for all infants born in the Yale New Haven hospital
46 system from February 19-May 26, 2020, a time period that began two weeks prior to the first
47 confirmed case in Connecticut (March 8). Routine SARS-CoV-2 PCR testing of all women who
48 presented to labor and delivery began on April 1, 2020. We adapted a standardized ELISA

49 Serology Assay² for detecting anti-SARS-CoV-2 antibody using newborn DBS. Anti-SARS-CoV-2
50 IgG was measured in all samples, and IgM was measured where the IgG result was positive. The
51 threshold for a positive result was set at the 99% confidence interval, at which 1% of true
52 negatives would be reported as false positives. Banked cord blood from infants born prior to
53 2019 was run as negative controls. Maternal demographic and clinical features were examined
54 in association with the likelihood of an antibody positive newborn using multivariable logistic
55 regression performed in STATA 16.1.

56 This study was deemed exempt from human subjects regulations by the Yale institutional
57 review board.

58 **Results**

59 The first positive DBS in the study was observed from an infant born in Connecticut on February
60 18, 2020 (**Figure 1**). Overall 182/3048 (5.9%) DBS tested were positive for anti-SARS-CoV-2 IgG.
61 None were positive for anti-SARS-CoV-2 IgM. Of the 182 infants with positive antibody results,
62 134 had mothers who underwent testing for COVID-19 by viral PCR prior to delivery, of which
63 65 (49%) had a positive test and 69 (51%) had a negative PCR test. All pre-2019 cord blood
64 samples were negative for SARS-CoV-2 IgG by this assay.

65

66 We examined the inter-relationship between daily newborn IgG antibody positive rates to
67 maternal and statewide COVID-19 infection rates. The daily positive proportion of DBS
68 specimens were predicted strongly by both maternal SARS-CoV-2 infection rate ($p<0.001$) and
69 statewide COVID-19 daily positive test counts per 100,000 people ($p=0.010$). Further

70 investigations using cross-correlation analysis demonstrated that daily newborn IgG antibody
71 positive rate strongly correlated with maternal SARS-CoV-2 infection rate at zero lag time
72 ($r=0.47$), and statewide COVID-19 positive test counts at a lag-time of 15-days ($r=0.45$).

73

74 We examined maternal demographics and clinical factors that may be associated with the
75 likelihood of an IgG+ newborn. Of the 92 mothers who tested positive for SARS-CoV-2 during
76 the universal screening period, 90 had complete demographic and clinical data. When
77 controlled for body mass index (BMI), hypertension, diabetes, COVID-19 symptoms, gestational
78 age, and time between maternal COVID-19 diagnosis and delivery (lag time), infants that were
79 antibody positive for COVID-19 were more likely to be born later during the study period
80 (adjusted OR, 1.05; 95% CI, 1.01-1.10, $p=0.01$), and to mothers with older maternal age
81 (adjusted OR, 1.13; 95% CI, 1.02-1.25, $p=0.01$). No significant associations were found for the
82 other factors.

83

84 **Discussion**

85 Our findings demonstrate utility of the newborn DBS SARS-CoV-2 antibody assay to detect past
86 maternal infection and suggest a use for DBS to measure population-level trends of COVID-19,
87 as well as a way to monitor for resurgence of this disease. The detection of seropositive
88 newborns prior to the availability of viral testing in CT indicates that DBS surveillance may be a
89 useful tool for COVID-19 surveillance where viral testing is limited. Most, but not all, mothers
90 who screened positive for SARS-CoV-2 during the study period delivered a newborn with

91 detectable anti-SAR-CoV-2 IgG antibody, a finding that may reflect the lag time in development
92 of detectable antibodies after infection.³

93

94 This study has limitations. Most mothers were screened for SARS-CoV-2 at the time of
95 hospitalization for delivery, but we were unable to determine the true date of maternal
96 infection. Because we did not have access to the date of infection or serum antibody testing
97 results for all mothers, we could not determine whether mothers who screened positive for
98 SARS-CoV-2 by PCR but delivered a seronegative newborn had poor antibody responses
99 themselves, had a remote infection with antibody responded that waned prior to delivery, or
100 whether there was inefficient transplacental transfer of antibody in these cases. However,
101 given that the majority of PCR positive mothers delivered seropositive newborns, this does not
102 appear to diminish the utility of DBS as a surveillance tool.

103

104 In this study, we demonstrate that levels of IgG in DBS reflect overall population-level trends in
105 case incidence, with a lag that is consistent with the time to development of detectable
106 antibodies after infection, making DBS antibody testing an attractive option for large-scale
107 population surveillance during the COVID-19 pandemic. As dried blood spots are routinely
108 collected from newborns, no additional sample collection is required, and specimens can be
109 stored for later assessment. Using DBS as a surveillance tool may therefore be particularly
110 advantageous in resource-poor settings, where innovative tools of field epidemiology will be
111 required in order to control the spread of the virus.

112

113

114

115

116

117 **Author Contributions:** *SFF had full access to all of the data in the study and takes responsibility*
118 *for the integrity of the data and the accuracy of the data analysis.*

119 *Concept and design: SFF and SBO*

120 *Acquisition, analysis, or interpretation of data: All authors.*

121 *Drafting of the manuscript: SFF, MN, PV, FL*

122 *Critical revision of the manuscript for important intellectual content: All authors.*

123 *Statistical analysis: MN, PV, FL*

124 *Administrative, technical, or material support: AR, SFF*

125 *Supervision: SFF*

126

127 **Additional contributions:** We acknowledge Dr. Wade Schulz who assisted with data acquisition.

128

129 **References**

- 130 1. Bjorkesten J, Enroth S, Shen Q, et al. Stability of Proteins in Dried Blood Spot Biobanks.
131 *Mol Cell Proteomics*. 2017;16(7):1286-1296.
- 132 2. Amanat F, Stadlbauer D, Strohmeier S, et al. A serological assay to detect SARS-CoV-2
133 seroconversion in humans. *Nat Med*. 2020.
- 134 3. Long QX, Liu BZ, Deng HJ, et al. Antibody responses to SARS-CoV-2 in patients with
135 COVID-19. *Nature medicine*. 2020;26(6):845-848.

136

137

138 **Figure 1: Rate of newborn COVID-19 positive antibody and cases in Connecticut from February to May**

139 **2020.** Daily positive rate (bars) and 7-day moving average (lines) of newborn IgG antibody (blue) in

140 relation to SARS-CoV-2 PCR in mothers (pink), and positive cases per 100,000 people in Connecticut

141 State (orange). Connecticut statewide data were retrieved from Hughes *et al.* (2020) and rate per

142 100,000 calculated using U.S. Census estimates.



